A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy
CONCLUSIONS: Our analysis showed that 1 vs. 2 cycles of MMC along with 5FU and radiation is associated with comparable treatment outcomes in general. However, in patients with stage IIIb and IIIc cancer, 2 doses of MMC were associated with improved ASCC-SS and distant DFS.PMID:38479443 | DOI:10.1016/j.radonc.2024.110219
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Kurian Joseph Zainab Al Habsi Aswin Abraham Arun Elangovan Sunita Ghosh Truo-Mingh Pham Devika Shreekumar Zeyana Ramji Kim Paulson Keith Tankel Nawaid Usmani Diane Severin Dan Schiller Clarence Wong Karen Mulder Hatim Karachiwala Corinne Doll Karen King T Source Type: research
More News: Anal Cancer | Cancer | Cancer & Oncology | Carcinoma | Radiology | Skin Cancer | Squamous Cell Carcinoma | Study